ARMR-100 is designed to bind fentanyl in the bloodstream before it crosses into the brain, and should reduce the drug’s central nervous system effects, including both its rewarding properties (euphoria) and its respiratory depressant effects (the mechanism of overdose death).

For individuals in recovery, reducing the rewarding “high” associated with a relapse may reduce the motivation to continue using and support longer-term abstinence. This is analogous to how vaccines against nicotine have been explored in smoking cessation. The degree to which ARMR-100 blunts the euphoric response will be evaluated in clinical trials.

Yes.

We have always focused on developing our technology using a platform approach. The ARMR team is actively working on multivalent formulations, new dosing methods, and new countermeasures to counter ever-changing threats infiltrating the drug supply.

Specifically, the hapten-carrier conjugate vaccine platform used in ARMR-100 has been applied in preclinical and early clinical studies targeting heroin, methamphetamine, and other substances. Each drug presents unique chemical and immunological challenges, but the fundamental approach is scientifically sound and largely the same.

Fentanyl analogs, including carfentanil and nitazenes, and non-opioid threats, such as medetomidine and xylazine, which are increasingly appearing in the illicit drug supply, are a particular area of interest for us, as our goal is to prevent the next crisis. The opportunity to make vaccines and new chemical entities against new synthetic drugs and toxic chemicals is being carefully assessed in our preclinical work.

No. 

It would only temporarily eliminate the utility of fentanyl, but this is not new or novel. A current example includes people who are allergic or have severe adverse reactions to fentanyl. Another example would be people currently suffering from use disorders who can’t receive fentanyl due to addiction history. Doctors can effectively administer anesthesia in both scenarios. 

In addition, it’s important to understand the vaccine’s specificity. The formulation works by generating antibodies that specifically bind to fentanyl. It is not designed to block all opioids and has not been shown to prevent other commonly used pain medications from having an effect.

Morphine, hydromorphone, oxycodone, and other commonly used opioid analgesics have distinct chemical structures and would not be affected by the vaccine. Emergency and perioperative physicians have a broad toolkit for pain management that extends well beyond fentanyl. That said, ARMR Sciences is actively working with anesthesiologists and emergency medicine specialists during the development process to ensure that clinical guidance around pain management in vaccinated individuals is clearly articulated in the labeling and communicated to healthcare providers.

We are targeting 6-12 months of protection. 

The duration of protection is one of the key questions our clinical program is designed to answer. As mentioned, based on what we know from other conjugate vaccines and early animal studies, we anticipate that the initial vaccine series will generate a durable antibody response for 6-12 months, but the precise duration in humans has not yet been established.

ARMR-100 is a conjugate vaccine comprising two active ingredients: the ARMR-100 antigen and the dmLT adjuvant. which means it works by linking a fentanyl-like molecule (a hapten) to a carrier protein that helps the immune system recognize and respond to it. This is the same general platform used in well-established vaccines, including those that protect against meningococcal disease and certain pneumococcal infections.

Long-term safety evaluation is a cornerstone of our clinical development plan. Because anti-drug vaccines generate antibodies that persist in the body over time, we are attentive to theoretical concerns, including: immune complex formation, off-target immune effects, and the durability and safety of the immune response itself.

These questions will be addressed through long-term follow-up in our clinical trials, dedicated post-marketing safety studies, and collaboration with large healthcare data systems capable of detecting rare adverse events at a population scale. Our post-marketing commitments will include a formal pharmacovigilance program, and we are committed to transparent reporting of all safety findings throughout the product lifecycle.

We are actively engaging with payers, health economists, and government stakeholders on this question. The economic case for coverage is compelling: overdoses cost the U.S. healthcare system, criminal justice system, and economy trillions of dollars annually. A vaccine that meaningfully reduces overdose mortality and morbidity should generate significant value from a payer perspective.

For occupational populations, we are exploring pathways through workers’ compensation, OSHA-related employer coverage, and direct government procurement (e.g., through the Department of Defense and the Department of Justice). For the OUD population, Medicaid and Medicare coverage will be critical, and we are engaging with CMS and relevant advisory bodies accordingly. We cannot provide specific coverage commitments at this stage, but this is a high priority.

The vaccine is being designed for those who are not seeking out lethal synthetic drugs and therefore would not be actively trying to overpower the vaccine’s protection. 

However, like anything, it is possible to overpower the medication if that’s the intent. The vaccine works by generating circulating antibodies that bind to fentanyl in the bloodstream, reducing the amount that reaches the brain. At typical street doses, the antibody response is designed to blunt or block the drug’s effects.

However, no vaccine provides absolute protection against arbitrarily high doses of any drug, and ARMR-100 is not intended to function as a physical barrier to drug use. The vaccine’s primary purpose is protection against accidental or occupational exposure, particularly in first responders and others who may be unknowingly exposed, and as a pharmacological support tool for individuals in recovery, where it may reduce the rewarding effects of relapse. Clinical studies will formally characterize the dose-response relationship and the limits of protection that the vaccine may provide.

No.

ARMR-100 does not contain heavy metals or thimerosal (the mercury-containing preservative that was historically used in some multi-dose vaccines).  The major non-fentanyl components of the vaccine are derived from inactive proteins found in other vaccines with well-established safety profiles.

We plan to make our ingredient information publicly available.

Several mechanisms are being considered and will be evaluated during the clinical development program:

Vaccination status could be documented in electronic health records (EHRs) and made accessible to treating providers through existing health information exchange systems. Patients may also be provided with a vaccination card or medical alert option — similar to those used for drug allergies — that they can carry or register with medical ID services. Public and professional education campaigns will be an important component of any rollout to ensure that providers are aware of and can interpret vaccination status. Specific guidance will be included in the product label or educational materials.

This is being tested, but there is no reason ARMR-100 can’t be used alongside currently available medications. 

Based on the mechanism of action, ARMR-100 is not expected to interfere with medications for opioid use disorder (MOUD). Buprenorphine and methadone act at opioid receptors directly and have chemical structures distinct from fentanyl; they would not be bound to any meaningful degree by fentanyl-specific antibodies. Naltrexone (and its extended-release formulation) works by blocking opioid receptors entirely and has no structural overlap with fentanyl.

The combination of ARMR-100 with MOUD may actually represent an important clinical opportunity offering complementary mechanisms of protection. Formal drug interaction studies are planned as part of the clinical development program.

No. 

Naloxone (Narcan) works by competitively blocking opioid receptors in the brain and displacing opioids from those receptors. ARMR-100 works upstream of this process, in the bloodstream, by binding fentanyl molecules before they reach the brain. These are entirely different and complementary mechanisms.

In someone who has been vaccinated and is nonetheless experiencing an overdose, whether due to a very high exposure or a fentanyl analog not fully covered by the vaccine, naloxone would still be expected to work. We want to be clear: ARMR-100 is not a replacement for naloxone, and individuals at risk for opioid overdose should continue to have access to naloxone regardless of vaccination status.

ARMR Sciences would like to make ARMR-100 available for anyone who is at risk for overdose exposure and subsequent harm. Ultimately, we envision this as an option for everyone to have, another tool in the toolset against overdose and addiction. 

This could include:

• College students and young adults who are at high risk of exposure due to experimentation and rebellious behavior. 
• Individuals in recovery from opioid use disorder for whom the vaccine may serve as a pharmacological support tool to reduce the risk of fatal overdose during a relapse.
• Occupational high-risk individuals, including law enforcement officers, firefighters, paramedics, military personnel, border patrol agents, and others whose professional duties.

Eligibility will ultimately be defined by regulatory agencies and vaccine-guidance-making bodies, such as the Advisory Committee on Immunization Practices (ACIP).

The same concern was once raised about seatbelts (“they’ll just drive more recklessly”), but we know this isn’t the case – it’s a safety precaution. Ultimately, we want to eliminate the lethality of the drug supply. Unfortunately, people are going to use drugs, but we believe they do not deserve to die from doing so. There are countless examples of people suffering from drug use disorders who have gone on to fully recover and achieve amazing things. We want to save innocent lives and help those suffering from use disorders on their path to recovery.

Also, we know relapse rates are extremely high for individuals suffering from use disorders (as high as 95%). Relapses can lead to overdoses, given the biological shock of reintroducing drugs to the human body. This is a scenario we would like to protect against as people work through their recovery. 

Saving a life creates an opportunity for recovery; death does not.

Reaching individuals with active opioid use disorder requires more than making a vaccine available in physician offices. ARMR Sciences is thinking carefully about access and implementation from the early stages of development.

This includes engaging with community health organizations, non-profits, substance use treatment centers, and public health agencies as key distribution partners. It also means working with payers and government programs, including Medicaid, which covers a disproportionate share of individuals with OUD, to ensure access.

It’s difficult to know, given our relatively early stage, but we want our cost to be accessible to anyone seeking protection. Pricing decisions will be made closer to the time of commercialization and will be informed by manufacturing costs, the outcome of payer and government negotiations, health technology assessments, and our commitment to making the vaccine accessible to those who need it most. We are not in a position to provide a specific price at this stage of development.

What we can say is that ARMR Sciences is committed to responsible pricing practices and is exploring a range of mechanisms, including tiered pricing for government and safety-net purchasers, to support broad access. We recognize that a vaccine that is not accessible is a vaccine that cannot save lives.